Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790868 · ClinicalTrials.gov registry record · Phase 2
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
A Phase 2 study of Panic Disorder, sponsored by Boston University Charles River Campus.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 4
- Study locations
NCT00790868: Completed Phase 2 study of Panic Disorder, sponsored by Boston University Charles River Campus.
NCT00790868 is a Phase 2 study of Panic Disorder that has completed, run by Boston University Charles River Campus. The registered enrollment target is 180 participants, below the 215-participant average among 25 other Panic Disorder trials with a reported enrollment target (16% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00790868, a Phase 2 study of Panic Disorder, has completed, sponsored by Boston University Charles River Campus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a 5-year double blind, randomized, controlled, trial conducted at three treatment sites, aimed at showing the acute and longer-term effects of DCS augmentation of exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that DCS can enhance the results of even a brief treatment strategy, the investigators are seeking to validate an approach that fits well with the practice limitations and applications of CBT in effectiveness studies.
Primary Outcome
The percent change in PDSS score from baseline to the relevant assessment points is the continuous primary outcome measure. The PDSS consists of seven items, each rated on a 0 to 4 scale (0 denoting none, and higher ratings reflecting greater degrees of symptom severity; for a possible range in scores from 0 to 28). In the tabular data below we present the total scores (sum of items).
Conditions Studied
Interventions
- DRUG placebo
- DRUG d-cycloserine
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston University - Boston
Connecticut
- Institute of Living - Hartford
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT00790868 record still lists
NCT00790868 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 215-participant average among 25 other Panic Disorder trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Panic Disorder appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00790868 reports a single indexed study location in Massachusetts, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT00790868 about?
NCT00790868 is a clinical study titled "Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder". This is a 5-year double blind, randomized, controlled, trial conducted at three treatment sites, aimed at showing the acute and longer-term effects of DCS augmentation of exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that DCS can enhance the results of even...
What is the current status of trial NCT00790868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2008-04. Estimated completion is 2014-08.
What conditions does trial NCT00790868 study?
This clinical trial studies the following conditions: Panic Disorder.
What interventions are being tested in trial NCT00790868?
The interventions under investigation include: placebo (DRUG), d-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00790868?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00790868 being conducted?
This trial has 4 study locations across Connecticut, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Panic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00790868's enrollment target sits among peer trials
180 9th of 25 higher than 16 of 25 other Panic Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Panic Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder
COMPLETED · Phase 2
-
Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
COMPLETED · Phase 2
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
RECRUITING · NA
-
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia